(Q53444169)

English

Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center.

scientific article published on 2 July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

Crohn's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Klaudia Farkas

1

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

Mariann Rutka

2

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

Anita Bálint

3

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

Ferenc Nagy

4

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

Renáta Bor

5

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

Ágnes Milassin

6

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

Zoltán Szepes

7

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

Tamás Molnár

8

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

language of work or name

0 references

publication date

2 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

Expert Opinion on Biological Therapy

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

15

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

9

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

1257-1262

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1064893

21 January 2018

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1064893

21 January 2018

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1064893

21 January 2018

Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1064893

21 January 2018

Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1064893

21 January 2018

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1064893

21 January 2018

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1064893

21 January 2018

ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1064893

21 January 2018

A review of CT-P13: an infliximab biosimilar

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2015.1064893

21 January 2018

Identifiers

10.1517/14712598.2015.1064893

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 May 2018

http://europepmc.org/abstract/MED/26134250

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53444169&oldid=1547886346"